Home LiteratureArticle Details
PMID: 10195071 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis.

Thorax ·Vol. 53 ·No. 12 ·1998-12-00 ·Pages 1018-21

Hull J, Thomson AH

Abstract

Disease severity in patients with cystic fibrosis shows marked variability. Attempts to explain this phenotypic heterogeneity on the basis of CFTR genotype have had limited success. A study was undertaken to test the hypothesis that naturally occurring variants of the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-alpha) and the detoxifying enzyme glutathione S-transferase M1 (GSTM1) could influence disease severity in cystic fibrosis. Fifty-three children with cystic fibrosis were studied. To allow for the effect of age, all clinical details were collected during the eighth year of age. The subjects were divided into groups, both according to the presence or absence of the TNF2 TNF-alpha -308 promoter polymorphism (n = 20), and by homozygosity for the null allele of GSTM1 (n = 26). Percentage predicted forced expiratory volume in one second (FEV1) and weight z scores were significantly lower in the TNF2 group (mean difference (95% confidence intervals) for FEV1 11.6% (1.7 to 21.5) and 0.59 (0.06 to 1.12) for weight z score). The Chrispin-Norman chest radiographic score was significantly higher and the Shwachman score was significantly lower in patients homozygous for the GSTM1 null allele. Two independent genetic factors have been identified which appear to influence disease severity in cystic fibrosis. These results support the contention that inflammation in cystic fibrosis contributes to tissue damage. Isolation of further such factors may lead to identification of patients at risk of more severe disease and allow targeted aggressive therapy in this group.

MeSH Terms
Alleles Child Cystic Fibrosis/genetics,physiopathology Cystic Fibrosis Transmembrane Conductance Regulator/genetics Female Forced Expiratory Volume Genotype Glutathione Transferase/genetics Humans Male Polymorphism, Genetic Risk Factors Tumor Necrosis Factor-alpha/genetics
Chemicals
CFTR protein, human Tumor Necrosis Factor-alpha Cystic Fibrosis Transmembrane Conductance Regulator Glutathione Transferase
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Hull J
Department of Paediatrics, John Radcliffe Hospital, Headington, Oxford, UK.
Thomson A H
References (31)
31 references, click to expand
  1. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion.
    Proc Natl Acad Sci U S A. 1988 Oct;85(19):7293-7 PMID: 3174634
  2. Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis.
    Hum Genet. 1997 Jun;99(6):822-6 PMID: 9187680
  3. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer.
    Hum Exp Toxicol. 1997 Jul;16(7):356-60 PMID: 9257159
  4. The TNF-alpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels.
    Diabetes. 1997 Sep;46(9):1468-72 PMID: 9287048
  5. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription.
    Mol Immunol. 1997 Apr;34(5):391-9 PMID: 9293772
  6. Detoxication enzymes and chemoprevention.
    Proc Soc Exp Biol Med. 1997 Nov;216(2):192-200 PMID: 9349688
  7. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis.
    Am J Respir Crit Care Med. 1997 Nov;156(5):1436-9 PMID: 9372657
  8. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.
    AMA J Dis Child. 1958 Jul;96(1):6-15 PMID: 13544726
  9. The systematic evaluation of the chest radiograph in cystic fibrosis.
    Pediatr Radiol. 1974;2(2):101-5 PMID: 15822331
  10. The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).
    N Engl J Med. 1990 Nov 29;323(22):1517-22 PMID: 2233932
  11. The human glutathione S-transferases: a case-control study of the incidence of the GST1 0 phenotype in patients with adenocarcinoma.
    Carcinogenesis. 1991 Jan;12(1):25-8 PMID: 1988177
  12. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation.
    Lancet. 1991 Mar 16;337(8742):631-4 PMID: 1671990
  13. Glutathione S-transferase class mu in French alcoholic cirrhotic patients.
    Hum Genet. 1991 Sep;87(5):628-30 PMID: 1916767
  14. Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis.
    Lancet. 1993 Jan 23;341(8839):189-93 PMID: 7678316
  15. Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis.
    Arch Dis Child. 1993 Mar;68(3):389-92 PMID: 8385438
  16. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product.
    Hum Mol Genet. 1992 Aug;1(5):353 PMID: 1363876
  17. alpha 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis.
    Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1665-70 PMID: 8256917
  18. Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population.
    Pediatrics. 1994 Jan;93(1):114-8 PMID: 7505422
  19. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours.
    Lancet. 1994 Jan 29;343(8892):266-8 PMID: 7905099
  20. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study.
    Cancer Res. 1994 Aug 1;54(15):4103-11 PMID: 8033143
  21. Polymorphism of the tumor necrosis factor genes in patients with dermatitis herpetiformis.
    Dermatology. 1994;189 Suppl 1:135-7 PMID: 7914110
  22. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.
    Nature. 1994 Oct 6;371(6497):508-10 PMID: 7935762
  23. Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508.
    Pediatr Pulmonol. 1994 Jul;18(1):3-7 PMID: 7970905
  24. Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis.
    Am J Clin Nutr. 1995 Apr;61(4):843-7 PMID: 7702029
  25. Inflammatory cytokines in cystic fibrosis lungs.
    Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2111-8 PMID: 8520783
  26. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor.
    Nat Genet. 1996 Mar;12(3):280-7 PMID: 8589719
  27. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress.
    Eur Respir J. 1996 Feb;9(2):334-9 PMID: 8777973
  28. Cystic fibrosis: genotypic and phenotypic variations.
    Annu Rev Genet. 1995;29:777-807 PMID: 8825494
  29. No primary association between the 308 polymorphism in the tumor necrosis factor alpha promoter region and insulin-dependent diabetes mellitus.
    Hum Immunol. 1996 Feb;45(2):137-42 PMID: 8882412
  30. Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus.
    J Rheumatol. 1996 Oct;23(10):1725-8 PMID: 8895148
  31. Pulmonary oxidative stress response in young children with cystic fibrosis.
    Thorax. 1997 Jun;52(6):557-60 PMID: 9227724
Article Info
Journal
Thorax
Abbr.
Thorax
ISSN
0040-6376
Published
1998-12-00
Pages
1018-21
Language
English
Region
England
NLM ID
0417353
PMCID
PMC1745152
Subset
IM
Grants
Wellcome Trust · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com